Treatment of COPD Exacerbations

Introduction to COPD Exacerbation Management

The American Thoracic Society recommends treatment of COPD exacerbations with short-acting bronchodilators, systemic corticosteroids for 5 days, and antibiotics for 5-7 days when increased sputum purulence is present along with increased dyspnea and/or sputum volume 1, 2, 3

The American Thoracic Society recommends short-acting inhaled β2-agonists, with or without short-acting anticholinergics, as initial bronchodilators for acute treatment of exacerbations 1, 2
Delivery can be via metered-dose inhalers with spacers or nebulizers, with no significant differences in FEV1 improvement between delivery methods, though nebulizers may be easier for sicker patients 2
Intravenous methylxanthines are not recommended due to their side effect profiles 2, 3

Antibiotics should be prescribed when patients present with increased dyspnea, increased sputum volume, and increased sputum purulence, or two cardinal symptoms if one is increased sputum purulence, or when requiring mechanical ventilation 1, 2
The recommended duration of antibiotic therapy is 5-7 days 1, 2, 4
Antibiotic choice should be based on local bacterial resistance patterns, with common first-line antibiotics including aminopenicillins with clavulanic acid, macrolides, and tetracyclines 1, 2
For patients with frequent exacerbations, severe airflow limitation, or requiring mechanical ventilation, sputum cultures should be obtained to identify resistant pathogens 1, 2

Systemic glucocorticoids improve lung function, oxygenation, and shorten recovery time and hospitalization duration, with a recommended dose of 40 mg prednisone per day for 5 days 1, 2, 3
Oral prednisolone is equally effective to intravenous administration 2, 3
Corticosteroids may be less effective in patients with lower blood eosinophil levels 2, 3

Antibiotics reduce short-term mortality by 77%, treatment failure by 53%, sputum purulence by 44%, and risk of early relapse, and hospitalization duration 1, 2
In patients requiring mechanical ventilation, studies show increased mortality and higher incidence of secondary nosocomial pneumonia when antibiotics are not given 2

More than 80% of COPD exacerbations can be managed on an outpatient basis, with the severity of the exacerbation and underlying disease determining whether inpatient or outpatient management is appropriate 1, 2

The most common organisms in COPD exacerbations are Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, and viruses, and for patients with frequent exacerbations or severe disease, consider broader coverage and obtain sputum cultures 2, 5, 6
Procalcitonin-guided antibiotic treatment may help reduce unnecessary antibiotic exposure while maintaining clinical efficacy 2

The presence of purulent green sputum is 94.4% sensitive and 77.0% specific for high bacterial load, making antibiotic therapy strongly indicated 7
The European Respiratory Society/American Thoracic Society guidelines confirm that antibiotics reduce treatment failure by 53%, short-term mortality by 77%, and extend time to next exacerbation 8, 9, 10

Levofloxacin causes significant QTc prolongation and is absolutely contraindicated in patients with baseline QTc >500 msec 7
The risk of torsades de pointes is unacceptably high in patients with pre-existing ventricular tachycardia 7
Macrolides are associated with increased risk of sudden cardiac death, particularly in patients with underlying cardiac disease 7

Amoxicillin-clavulanate does not prolong QTc interval and is safe in patients with cardiac arrhythmias 7
Amoxicillin-clavulanate provides excellent coverage for the most common COPD pathogens: S. pneumoniae, H. influenzae, and M. catarrhalis 7, 9

If QTc >500 msec or history of ventricular arrhythmias, avoid fluoroquinolones and macrolides 7
First-line for moderate COPD without cardiac contraindications: amoxicillin-clavulanate, fluoroquinolones, or macrolides 7, 9
With cardiac contraindications, amoxicillin-clavulanate is the only safe option among first-line agents 7

Amoxicillin-clavulanate 875/125 mg orally twice daily for 5-7 days 9
The 2000/125 mg twice-daily formulation may be considered for enhanced coverage of resistant S. pneumoniae 7

Withholding antibiotics increases risk of treatment failure by 53% and mortality by 77% 9
Longer courses of antibiotics do not improve outcomes and increase resistance risk 9

Do not prescribe fluoroquinolones or macrolides in patients with QTc >500 msec, history of ventricular arrhythmias, or concurrent use of other QT-prolonging medications 7